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ABSTRACT
Mutations can increase the ceftazidimase activity
of CTX-M-3 b-lactamase, as seen with its wide-
spread variant CTX-M-15. This study compared
the frequencies of emerging ceftazidime resist-
ance in isogenic wild-type and hyper-mutable
mutS CTX-M-3-producing Escherichia coli strains,
and sequenced the mutant blaCTX-M alleles selec-
ted. Ceftazidime resistance emerged more readily
in the hyper-mutable background than in the
wild-type strain. All selected CTX-M mutants, in
both the wild-type and the mutS derivatives, had
single amino-acid changes at position 167, inclu-
ding a novel Pro167Gln substitution. These data
emphasise the potential for further diversification
of CTX-M enzymes.
Keywords b-Lactamase, ceftazidime, CTX-M en-
zymes, Escherichia coli, resistance, selection
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The extensive use of third-generation cephalospo-
rins seems likely to have played a major role in the
selection of CTX-M enzymes, with some sugges-
tions that cefepime and ceftriaxone may be par-
ticularly selective [1]. Most CTX-M enzymes have
weak catalytic activity against ceftazidime, but
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changes to amino-acids 167 and 240 are associated
with increased ceftazidimase activity [2,3]. Thus,
at least seven variants from three of the five
phylogenetic groups of CTX-M enzymes confer
increased resistance to ceftazidime: the group 1
enzymes CTX-M-15, -23 and -42; the group 9
enzymes CTX-M-16, -19 and -27; and finally, CTX-
M-25 [2–7]. CTX-M-15, one of the commonest
CTX-M variants in Europe [2], including in the UK
[8], is a ceftazidime-hydrolysing variant of CTX-
M-3, differing from its parent only by an aspartate-
to-glycine substitution at position 240 [6].
A factor that has the potential to accelerate the
evolution of CTX-M variants with ceftazidimase
activity is hyper-mutability, arising via defects in
the methyl-directed, post-replication DNA mis-
match repair system, notably in the MutS protein
[9–11]. Therefore, the present study compared the
emergence of ceftazidime-resistant mutants from
isogenic CTX-M-3-producing wild-type and
MutS-negative Escherichia coli.
The blaCTX-M-3 gene was amplified from an
E. coli clinical isolate using the primer pair
PROM+ ⁄preCTX-M3B, as described previously
[6], and was cloned into the low-copy-number
vector pBBR1MCS-2 [12]. The recombinant vector,
designated pCTX-M-3, was electroporated into
electrocompetent isogenic E. coli wild-type 1411
(WT) and hyper-mutable MutS-negative 1413
(mutS) strains [11]. Transformants were selected
overnight at 37C on nutrient agar containing
kanamycin 50 mg ⁄L and cefotaxime 2 mg ⁄L
(Sigma-Aldrich, Poole, UK). Cefotaxime MICs
for WT and mutS transformants harbouring the
recombinant vector pCTX-M-3 were 128-fold
higher than the ceftazidime MICs (Table 1), with
clavulanate restoring cephalosporin susceptibil-
ity. Ceftazidime MICs were only 1–2 mg ⁄L, as
determined according to British Society for Anti-
microbial Chemotherapy guidelines [13].
Ceftazidime-resistant mutants of the WT and
mutS strains carrying pCTX-M-3 were selected on
nutrient agar containing ceftazidime (Glaxo-
SmithKline, Worthing, UK) at 4 · MIC (i.e.,
4 mg ⁄L for WT and 6 mg ⁄L for mutS) from three
independent cultures in quadruple experiments
using a controlled inoculum. The methodology
has been described in detail previously [11]. After
incubation at 37C for 18 h, the ceftazidime-
resistant colonies were counted and mutation
frequencies were calculated, taking plate counts
of viable bacteria on drug-free agar as the denom- T
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inator. The frequency of mutation to ceftazidime
resistance was c. 60-fold higher with the mutS
strain harbouring pCTX-M-3 (1.29 · 10)5 ±
4.9 · 10)6) than with the WT strain harbouring
the same plasmid (2 · 10)7 ± 4.3 · 10)8).
Both strands of blaCTX-M were sequenced from
the parental WT and mutS recombinant strains,
and from three WT and five mutS mutants. All
eight mutants had single-base substitutions
resulting in amino-acid changes at position 167.
All five mutants derived in the mutS background
had a Pro167Ser substitution, which has been
associated with increased ceftazidimase activity
in the group 9 enzyme CTX-M-19 [5] and in
laboratory mutants of CTX-M-2 (group 2) [14],
although not previously in group 1 enzymes such
as CTX-M-3. Two mutants, both derived in the
WT background, had a Pro167Thr substitution,
corresponding to the recently identified CTX-M-
42 enzyme [7]; this substitution is also present in
the ceftazidime-hydrolysing group 1 enzyme
CTX-M-23 [3]. The remaining ceftazidime-resist-
ant WT mutant had a novel Pro167Gln substitu-
tion, which is a change not described previously
in any wild-type CTX-M variants. None of the
selected mutants corresponded to CTX-M-15, the
commonest ceftazidimase variant of CTX-M-3
among clinical isolates.
All of the randomly selected mutants were
clearly resistant to ceftazidime, with MICs in-
creased ‡ 32-fold (Table 1). Re-transformation of
the plasmids into new cultures of their WT or mutS
hosts confirmed that ceftazidime resistance was
conferred by the altered b-lactamases, but varia-
tions in MICs among transformants with the same
enzyme mutant suggest that other factors, such as
the level of enzyme expression, may also play a
role. The MICs of ceftazidime were higher than
those of cefotaxime for most mutants, as has also
been observed for other CTX-M variants with
changes at position 167, e.g., CTX-M-19, -23 and -42
[3,5,7]. In contrast, cefepime MICs were decreased
up to eight-fold compared with strains harbouring
non-mutated blaCTX-M-3. Such an exchange in cat-
alytic activity between ceftazidime and cefepime
was also observed for CTX-M-19 and its progenitor
CTX-M-18 [5], and for CTX-M-2 and its in-vitro
ceftazidimase mutants [14]. Notably, and perhaps
explaining its clinical success, CTX-M-15 confers
high-level resistance to both cefepime and cefotax-
ime as well as ceftazidime. All of the studied
ceftazidime-resistant mutants remained suscept-
ible to carbapenems, and to combinations of a
cephalosporin with clavulanate and piperacillin–
tazobactam.
In summary, mutations in blaCTX-M-3 conferring
ceftazidime resistance emerged more readily in a
hyper-mutable background, but also occurred in
the WT host. The selected mutants had changes at
residue 167, a site shown previously to affect
ceftazidimase activity in CTX-M enzymes. The
novel Pro167Gln substitution indicates the further
evolutionary potential of CTX-M enzymes. All of
the observed changes increased the ability to
confer resistance against ceftazidime, but tended
to reduce resistance to cefepime. Repeated and
varying selection with cefepime, as well as ceft-
azidime, in a clinical setting might encourage the
evolutionary success of CTX-M-15 variants rather
than the types observed here. As mutator E. coli
strains with lesions in mutS occur in natural
bacterial populations [10], hyper-mutable E. coli
strains may play a role in the evolutionary
diversification of CTX-M enzymes.
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ABSTRACT
A cloned 5248-bp EcoRI fragment from the Kleb-
siella pneumoniae transferable plasmid pKP53
(> 70 kb) containing blaSHV-5 was sequenced.
Insertion sequences IS26 and IS5 were found
downstream from blaSHV-5. The DNA sequences
of the genetic environment surrounding blaSHV-5
were homologous to plasmid p1658 ⁄ 97 from
Escherichia coli, containing a truncated recF gene
and a truncated deoR gene upstream and down-
stream from blaSHV-5, respectively. RecF may be
involved in blaSHV-5 translocation to the plasmid
by RecF-dependent recombination. This novel
genetic environment may be associated with the
successful proliferation and ⁄ or expression of
SHV-5 in K. pneumoniae strains from Taiwan.
Keywords blaSHV gene, DNA sequence, insertion
sequence, Klebsiella pneumoniae, RecF, sequencing
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Extended-spectrum b-lactamases (ESBLs), such as
TEM, SHV and CTX-M types, are common in
Klebsiella pneumoniae, where they confer resistance
to broad-spectrum b-lactams [1,2]. Despite an
increasing incidence of ESBLs worldwide, infor-
mation concerning the mobilisation of ESBL genes
remains scarce [2,3]. Mobile blaSHV-5 and blaSHV-2a
genes may have evolved from a chromosomally
located blaSHV-1 gene following IS26-dependent
mobilisation [3]. In addition to transfer of ESBL
genes by conjugative plasmids [2], insertion
sequence ISEcp1 and a sul1-type class 1 integron
have been implicated in the spread of blaCTX-M
[4,5].
In Taiwan, SHV-5 represents about 60% of all
ESBLs produced by K. pneumoniae isolates [6].
Although plasmid dissemination and clonal
spread may contribute to proliferation of ESBLs,
most SHV-5 producers with different plasmid
profiles are clonally unrelated [6,7]. It is not easy
to explain why SHV-5 predominates among these
sporadic isolates. Although blaSHV-5 has been
found 5¢ to an integron that contains aminogly-
coside resistance determinants on plasmids such
as pACM1 from Klebsiella oxytoca [8], pSEM from
Salmonella enterica serotype Typhimurium [9], and
p1658 ⁄ 97 from Escherichia coli (accession no.
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